2.50
Hdl Handle:
http://hdl.handle.net/2336/30733
Title:
Raloxifene for older women: a review of the literature
Authors:
Hansdottir, Helga
Citation:
Clin Interv Aging. 2008, 3(1):45-50
Issue Date:
2008
Abstract:
Raloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) which is used for prevention and treatment of postmenopausal osteoporosis. Raloxifene decreases the incidence of vertebral fractures by 30%-50% in postmenopausal women with osteoporosis but has not been shown to decrease the incidence of hip fractures or other non-vertebral fractures. At the present time, estrogen-replacement therapy and bisphosphonate treatment are the only medical treatments that are proven to prevent hip fractures with the exception of vitamin D and calcium replacement, which has been shown to prevent hip fractures in elderly individuals and nursing home residents. Raloxifene has been shown to have additive effects on bone turnover and bone mineral density (BMD) when used along with alendronate and teriparatide. Raloxifene could have a role in renal failure as it has been shown to increase BMD of the vertebra over 1 year of therapy. Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer. The increased incidence of venous thromboembolism is the main concern of raloxifene therapy and previous history of venous thromboembolism is a contraindication for use of raloxifene. Raloxifene has a role in treatment of vertebral osteoporosis in older women. The decision to use raloxifene should be based on evaluation of fracture risk and on potential other benefits than fracture reduction along with consideration of side effects.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.dovepress.com/articles.php?article_id=228

Full metadata record

DC FieldValue Language
dc.contributor.authorHansdottir, Helga-
dc.date.accessioned2008-07-01T09:26:39Z-
dc.date.available2008-07-01T09:26:39Z-
dc.date.issued2008-
dc.date.submitted2008-07-01-
dc.identifier.citationClin Interv Aging. 2008, 3(1):45-50en
dc.identifier.issn1176-9092-
dc.identifier.pmid18488877-
dc.identifier.urihttp://hdl.handle.net/2336/30733-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractRaloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) which is used for prevention and treatment of postmenopausal osteoporosis. Raloxifene decreases the incidence of vertebral fractures by 30%-50% in postmenopausal women with osteoporosis but has not been shown to decrease the incidence of hip fractures or other non-vertebral fractures. At the present time, estrogen-replacement therapy and bisphosphonate treatment are the only medical treatments that are proven to prevent hip fractures with the exception of vitamin D and calcium replacement, which has been shown to prevent hip fractures in elderly individuals and nursing home residents. Raloxifene has been shown to have additive effects on bone turnover and bone mineral density (BMD) when used along with alendronate and teriparatide. Raloxifene could have a role in renal failure as it has been shown to increase BMD of the vertebra over 1 year of therapy. Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer. The increased incidence of venous thromboembolism is the main concern of raloxifene therapy and previous history of venous thromboembolism is a contraindication for use of raloxifene. Raloxifene has a role in treatment of vertebral osteoporosis in older women. The decision to use raloxifene should be based on evaluation of fracture risk and on potential other benefits than fracture reduction along with consideration of side effects.en
dc.language.isoenen
dc.publisherDove Medical Pressen
dc.relation.urlhttp://www.dovepress.com/articles.php?article_id=228en
dc.subject.meshBone and Bonesen
dc.subject.meshBreast Neoplasmsen
dc.subject.meshCardiovascular Systemen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshMiddle Ageden
dc.subject.meshOsteoporosis, Postmenopausalen
dc.subject.meshRaloxifeneen
dc.subject.meshRisk Factorsen
dc.subject.meshSelective Estrogen Receptor Modulatorsen
dc.titleRaloxifene for older women: a review of the literatureen
dc.typeArticleen
dc.contributor.departmentDepartment of Geriatrics, Landspitali University Hospital, Landakoti, Reykjavik, Iceland. helgah@lsh.isen
dc.identifier.journalClinical interventions in agingen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.